We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tyratech (DI) | LSE:TYRU | London | Ordinary Share | COM SHS USD0.001 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.00 | 2.80 | 3.20 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMTYR TIDMTYRU
RNS Number : 4329F
TyraTech, Inc.
28 July 2016
Strictly Embargoed for 07.00 on 28 July 2016
TyraTech, Inc.
("TyraTech" or the "Company")
Pre Close Trading Update
TyraTech, Inc. (AIM: TYR and TYRU), a life sciences technology company focused on nature-derived insect and parasite control products gives the following update on trading ahead of the announcement of its half year results to 30 June 2016.
The Company's trading performance in the first half continues the upward trend from prior periods, with unit sales of the Vamousse(R) head lice product line continuing to progress and operating expense efficiencies now being realised. These trends are anticipated to continue throughout the second half. The Board expects the net loss over the year to remain in line with current market expectations.
Vamousse
Unit sales of Vamousse were in line with expectations, showing strong growth over the corresponding period for 2015 across all geographies and customers. Vamousse continues to establish itself as a leading brand and is performing well in the market against competitor products, gaining market share.
Revenues associated with these sales have been modestly impacted by currency translation effects on UK sales and by revenue recognition factors, due to sale or return associated with one new US customer. These impacts are expected to continue through the rest of the year.
PureScience(TM)
The PureScience portfolio of animal health products is showing good results in field and customer trials, and three products were launched for poultry and swine production at the end of the half.
The roll-out of PureScience in the first half was slower than anticipated mainly due to the time of completing the field trials and it is now expected that the revenue impact will be in the second half of the year.
The Company expects to announce its interim results in mid-September 2016 and will give a further update at that time.
*-ends-*
For further information please visit: www.tyratech.com or contact:
TyraTech Inc. Tel: +1 919 Bruno Jactel, Chief Executive 415 4340 Officer Tel: +1 919 Erica Boisvert, Chief Financial 415 4287 Officer SPARK Advisory Partners Limited Tel: +44 20 (Nominated Adviser) 3368 3551 Matt Davis / Mark Brady Allenby Capital Limited (Joint Tel: +44 20 Broker) 3328 5656 Chris Crawford Whitman Howard Limited (Joint Tel: +44 20 Broker) 7659 1250 Ranald McGregor-Smith Belvedere Communications (PR) John West / Kim van Beeck Tel: +44 20 3567 0510
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTPGUAUMUPQGAM
(END) Dow Jones Newswires
July 28, 2016 02:00 ET (06:00 GMT)
1 Year Tyratech (DI) Chart |
1 Month Tyratech (DI) Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions